Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans

Lankin, Vadim Z.; Konovalova, Galina G.; Domogatsky, Sergey P.; Tikhaze, Alla K.; Klots, Igor N.; Ezhov, Marat V.

doi:10.3390/ijms241310471

Open AccessCommunication

Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans

by

Vadim Z. Lankin

^1,*,

Galina G. Konovalova

¹,

Sergey P. Domogatsky

¹,

Alla K. Tikhaze

¹,

Igor N. Klots

²

and

Marat V. Ezhov

³

¹

Department for Free Radical Biochemistry, E.I. Chazov’ National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow 121552, Russia

²

Research Institute of Medical Primatology, National Research Center “Kurchatov’ Institute”, Sochi 354376, Russia

³

Laboratory of Lipid Disorders, E.I. Chazov’ National Medical Research Center of Cardiology, Russian Ministry of Health, Moscow 121552, Russia

^*

Author to whom correspondence should be addressed.

Int. J. Mol. Sci. 2023, 24(13), 10471; https://doi.org/10.3390/ijms241310471

Submission received: 5 June 2023 / Revised: 14 June 2023 / Accepted: 16 June 2023 / Published: 21 June 2023

(This article belongs to the Special Issue Free Radical Oxidation and Natural Antioxidants: Molecular Aspect Action)

Download

Browse Figures

Versions Notes

Abstract

The kinetics of elimination of various dicarbonyl-modified low-density lipoproteins from the bloodstream of Macaca mulatta monkeys were investigated. The low-density lipoproteins (LDL) in the monkey blood plasma were isolated by density gradient ultracentrifugation and labeled in vitro with the fluorescent dye FITC; thereupon, they were modified with different natural low molecular-weight dicarbonyls: malondialdehyde (MDA), glyoxal, or methylglyoxal. The control native FITC-labeled LDL and dicarbonyl-modified FITC-labeled LDL were injected into the monkey’s ulnar vein; thereafter, blood samples were taken at fixed time intervals during 24 h. The plasma level of FITC-labeled LDL was determined with spectrofluorimetry. The study established that glyoxal- and monkeysglyoxal-labeled LDL circulated in monkey virtually at the same time as native (non-modified) LDL. In contrast, MDA-modified LDL disappeared from the blood extremely rapidly. Administration of the PCSK9 inhibitor involocumab (which increases LDL utilization) to patients with coronary heart disease (CHD) was found to significantly reduce levels of MDA-modified LDL.

Keywords: oxidative stress; dicarbonyl-modified LDL; malondialdehyde (MDA); glyoxal; methylglyoxal; atherosclerosis

Share and Cite

MDPI and ACS Style

Lankin, V.Z.; Konovalova, G.G.; Domogatsky, S.P.; Tikhaze, A.K.; Klots, I.N.; Ezhov, M.V. Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans. Int. J. Mol. Sci. 2023, 24, 10471. https://doi.org/10.3390/ijms241310471

AMA Style

Lankin VZ, Konovalova GG, Domogatsky SP, Tikhaze AK, Klots IN, Ezhov MV. Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans. International Journal of Molecular Sciences. 2023; 24(13):10471. https://doi.org/10.3390/ijms241310471

Chicago/Turabian Style

Lankin, Vadim Z., Galina G. Konovalova, Sergey P. Domogatsky, Alla K. Tikhaze, Igor N. Klots, and Marat V. Ezhov. 2023. "Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans" International Journal of Molecular Sciences 24, no. 13: 10471. https://doi.org/10.3390/ijms241310471

APA Style

Lankin, V. Z., Konovalova, G. G., Domogatsky, S. P., Tikhaze, A. K., Klots, I. N., & Ezhov, M. V. (2023). Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans. International Journal of Molecular Sciences, 24(13), 10471. https://doi.org/10.3390/ijms241310471

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Clearance and Utilization of Dicarbonyl-Modified LDL in Monkeys and Humans

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI